138 related articles for article (PubMed ID: 34973040)
1. Dual specificity phosphatase 22 relates to skin lesion degree and biologics history, while its longitudinal elevation during treatment reflects better outcome in psoriasis patients.
E C; Fang Y; Wu S; Meng Z; Qin G; Yang J
J Clin Lab Anal; 2022 Feb; 36(2):e24199. PubMed ID: 34973040
[TBL] [Abstract][Full Text] [Related]
2. Measurement of synovium and serum dual specificity phosphatase 22 level: Their inter-correlation and potency as biomarkers in rheumatoid arthritis.
Qian C; Chen J; Xu X; Liu Q; Gu M; Lu S; Bai H; Wang Q; Xue M
J Clin Lab Anal; 2022 Jan; 36(1):e24111. PubMed ID: 34811816
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-146a and microRNA-146b deficiency correlates with exacerbated disease activity, and their longitude increment relates to etanercept response in psoriasis patients.
Shen H; Wang D; Zhan M; Ding H; Zhao H
J Clin Lab Anal; 2022 Feb; 36(2):e24198. PubMed ID: 34952998
[TBL] [Abstract][Full Text] [Related]
4. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
[TBL] [Abstract][Full Text] [Related]
5. Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients.
Jin W; Zhang S; Duan Y
Dermatology; 2019; 235(1):55-64. PubMed ID: 30408786
[TBL] [Abstract][Full Text] [Related]
6. Measurement of circulating miRNA-125a exhibits good value in the management of etanercept-treated psoriatic patients.
Pei D; Cao J; Qin G; Wang X
J Dermatol; 2020 Feb; 47(2):140-146. PubMed ID: 31820498
[TBL] [Abstract][Full Text] [Related]
7. JNK pathway-associated phosphatase associates with rheumatoid arthritis risk, disease activity, and its longitudinal elevation relates to etanercept treatment response.
Sun L; Tu J; Chen X; Dai M; Xia X; Liu C; Zhou Y
J Clin Lab Anal; 2021 Apr; 35(4):e23709. PubMed ID: 33547838
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal change in CDC42 in psoriasis: correlation with disease activity and treatment response.
Xu B; Fan L; Liu Q; Guo B; Yang T; Zhang Y
Biomark Med; 2023 Aug; 17(16):657-666. PubMed ID: 37934043
[TBL] [Abstract][Full Text] [Related]
9. JNK Pathway-Associated Phosphatase as a Serum Marker for Disease Activity and Treatment Outcome of Juvenile Idiopathic Arthritis.
Zhu S; Lv H; Luo Y; Huang Q; Shen J
Tohoku J Exp Med; 2021 Jan; 253(1):19-28. PubMed ID: 33441511
[TBL] [Abstract][Full Text] [Related]
10. Plasma miR-126 expression correlates with risk and severity of psoriasis and its high level at baseline predicts worse response to Tripterygium wilfordii Hook F in combination with acitretin.
Duan Y; Zou J; Mao J; Guo D; Wu M; Xu N; Zhou J; Zhang Y; Guo W; Jin W
Biomed Pharmacother; 2019 Jul; 115():108761. PubMed ID: 31100542
[TBL] [Abstract][Full Text] [Related]
11. Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept.
Yang A; Xin X; Yang W; Li M; Yang W; Li L; Liu X
Ann Dermatol Venereol; 2019 May; 146(5):363-371. PubMed ID: 31047699
[TBL] [Abstract][Full Text] [Related]
12. Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value.
Elberdín L; Outeda M; Salvador P; Paradela S; Fernández-Torres RM; Iglesias R; Fonseca E; Martín I
Int J Clin Pharm; 2016 Oct; 38(5):1142-8. PubMed ID: 27436193
[TBL] [Abstract][Full Text] [Related]
13. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of dual specificity phosphatase 22 in colorectal cancer and its potential prognostic relevance for stage IV CRC patients.
Yu D; Li Z; Gan M; Zhang H; Yin X; Tang S; Wan L; Tian Y; Zhang S; Zhu Y; Lai M; Zhang D
Tumour Biol; 2015 Nov; 36(11):8531-5. PubMed ID: 26032091
[TBL] [Abstract][Full Text] [Related]
15. Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors.
Qian M; Song NJ
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(13):4299-4309. PubMed ID: 30024620
[TBL] [Abstract][Full Text] [Related]
16. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.
Kanelleas A; Liapi C; Katoulis A; Stavropoulos P; Avgerinou G; Georgala S; Economopoulos T; Stavrianeas NG; Katsambas A
Clin Exp Dermatol; 2011 Dec; 36(8):845-50. PubMed ID: 21790728
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study.
Xie F; Wang R; Zhao ZG; Meng XF; Lin BW; Yang J; Wang WJ; Ding XY; Yang Y; Zhao H; Li CX; Li HJ; Zhou Y
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):943-947. PubMed ID: 29270758
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
19. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
Bagel J; Samad AS; Stolshek BS; Aras GA; Chung JB; Kricorian G; Kircik LH
J Drugs Dermatol; 2018 Oct; 17(10):1078-1082. PubMed ID: 30365588
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
Papp KA; Yang M; Sundaram M; Jarvis J; Betts KA; Bao Y; Signorovitch JE
Value Health; 2018 Jan; 21(1):1-8. PubMed ID: 29304933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
